Literature DB >> 21082698

The MG-QOL15 for following the health-related quality of life of patients with myasthenia gravis.

Ted M Burns1, C K Grouse, Gil I Wolfe, Mark R Conaway, Donald B Sanders.   

Abstract

The MG-QOL15 is helpful in informing the clinician about the patient's perception of the extent of and dissatisfaction with myasthenia gravis (MG)-related dysfunction. The aims of this study were to determine the usefulness of the MG-QOL15 for following individuals with MG and to guide clinical researchers who plan to use the MG-QOL15. We assessed sensitivity and specificity for detecting clinical change and evaluated test-retest reliability. Sensitivities and specificities of various cut-points of change in scores are presented. Also presented are means and standard deviations of MG-QOL15 scores for all patients and for subgroups of patients. The test-retest reliability coefficient was 98.6%. The MG-QOL15 has an acceptable longitudinal construct validity. We consider this instrument to be most useful for informing the clinician about the patient's perception and tolerance of MG-related dysfunction. More objective measures, such as the MG Composite, should also be used to follow disease severity.

Entities:  

Mesh:

Year:  2011        PMID: 21082698     DOI: 10.1002/mus.21883

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  13 in total

1.  Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): A randomized, controlled trial.

Authors:  Michael Benatar; Michael P Mcdermott; Donald B Sanders; Gil I Wolfe; Richard J Barohn; Richard J Nowak; Michael Hehir; Vern Juel; Hans Katzberg; Rabi Tawil
Journal:  Muscle Nerve       Date:  2016-01-27       Impact factor: 3.217

2.  The results of video-assisted thoracoscopic thymectomies in Saint Petersburg, Russia: 20-year of experience.

Authors:  Piotr Yablonsky; Vadim Pischik; Marina G Tovbina; Mikhail Atiukov
Journal:  J Vis Surg       Date:  2017-08-21

Review 3.  Immunotherapy in myasthenia gravis in the era of biologics.

Authors:  Marinos C Dalakas
Journal:  Nat Rev Neurol       Date:  2019-02       Impact factor: 42.937

4.  A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis.

Authors:  Mamatha Pasnoor; Jianghua He; Laura Herbelin; Ted M Burns; Sharon Nations; Vera Bril; Annabel K Wang; Bakri H Elsheikh; John T Kissel; David Saperstein; J Aziz Shaibani; Carlayne Jackson; Andrea Swenson; James F Howard; Namita Goyal; William David; Matthew Wicklund; Michael Pulley; Mara Becker; Tahseen Mozaffar; Michael Benatar; Robert Pazcuzzi; Ericka Simpson; Jeffrey Rosenfeld; Mazen M Dimachkie; Jeffrey M Statland; Richard J Barohn
Journal:  Neurology       Date:  2016-06-15       Impact factor: 9.910

5.  Development and validation of the Myasthenia Gravis Impairment Index.

Authors:  Carolina Barnett; Vera Bril; Moira Kapral; Abhaya Kulkarni; Aileen M Davis
Journal:  Neurology       Date:  2016-07-08       Impact factor: 9.910

6.  Cross-sectional analysis of the Myasthenia Gravis Patient Registry: Disability and treatment.

Authors:  Gary Cutter; Haichang Xin; Inmaculada Aban; Ted M Burns; Phillip H Allman; Ramin Farzaneh-Far; Petra W Duda; Henry J Kaminski
Journal:  Muscle Nerve       Date:  2019-10-09       Impact factor: 3.217

7.  Determinants of quality of life in Brazilian patients with myasthenia gravis.

Authors:  Aline Mansueto Mourão; Rodrigo Santiago Gomez; Luiz Sergio Mageste Barbosa; Denise da Silva Freitas; Elizabeth Regina Comini-Frota; Arthur Kummer; Stella Maris Aguiar Lemos; Antonio Lucio Teixeira
Journal:  Clinics (Sao Paulo)       Date:  2016-07       Impact factor: 2.365

8.  The benefits and tolerance of exercise in myasthenia gravis (MGEX): study protocol for a randomised controlled trial.

Authors:  Simone Birnbaum; Jean-Yves Hogrel; Raphael Porcher; Pierre Portero; Bernard Clair; Bruno Eymard; Sophie Demeret; Guillaume Bassez; Marcela Gargiulo; Estelle Louët; Sonia Berrih-Aknin; Asmaa Jobic; Philippe Aegerter; Philippe Thoumie; Tarek Sharshar
Journal:  Trials       Date:  2018-01-18       Impact factor: 2.279

9.  Understanding side effects of therapy for myasthenia gravis and their impact on daily life.

Authors:  Elizabeth Dansie Bacci; Karin S Coyne; Jiat-Ling Poon; Linda Harris; Audra N Boscoe
Journal:  BMC Neurol       Date:  2019-12-21       Impact factor: 2.474

10.  Intravenous immunoglobulins may prevent prednisone-exacerbation in myasthenia gravis.

Authors:  Laura Díez-Porras; Christian Homedes; Maria Antonia Alberti; Valentina Vélez-Santamaría; Carlos Casasnovas
Journal:  Sci Rep       Date:  2020-08-11       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.